{"doi":"10.1093/annonc/mdz394.070","title":"SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)","abstract":null,"journal":"Annals of Oncology","year":2019,"id":623738,"datarank":0.7953390425457018,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.3794507342097345,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.3794507342097345,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":11,"citers_with_citation_signal":9,"citers_with_endowment":9,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1612115,"name":"A. Needham","orcid":null,"position":1,"is_corresponding":false},{"id":1612116,"name":"P.G. Corrie","orcid":null,"position":2,"is_corresponding":false},{"id":1612117,"name":"S. Danson","orcid":null,"position":3,"is_corresponding":false},{"id":172918,"name":"J. Evans","orcid":null,"position":4,"is_corresponding":false},{"id":1612118,"name":"S. Ochsenreither","orcid":null,"position":5,"is_corresponding":false},{"id":662211,"name":"S. Kumar","orcid":"0000-0002-3414-4091","position":6,"is_corresponding":false},{"id":640305,"name":"A. Goodman","orcid":"0000-0001-7913-9862","position":7,"is_corresponding":false},{"id":1612119,"name":"J.M.G. Larkin","orcid":null,"position":8,"is_corresponding":false},{"id":1612120,"name":"I. Karydis","orcid":null,"position":9,"is_corresponding":false},{"id":1612122,"name":"N.M. Steven","orcid":null,"position":10,"is_corresponding":false},{"id":1612125,"name":"P. Lorigan","orcid":null,"position":11,"is_corresponding":false},{"id":1612127,"name":"R. Plummer","orcid":null,"position":12,"is_corresponding":false},{"id":412685,"name":"P. Patel","orcid":null,"position":13,"is_corresponding":false},{"id":1612130,"name":"H.M. Shaw","orcid":null,"position":14,"is_corresponding":false},{"id":1612131,"name":"S. Leyvraz","orcid":null,"position":15,"is_corresponding":false},{"id":1612132,"name":"C. Rawcliffe","orcid":null,"position":16,"is_corresponding":false},{"id":1612133,"name":"E.E. Psarelli","orcid":null,"position":17,"is_corresponding":false},{"id":1612134,"name":"L. Handley","orcid":null,"position":18,"is_corresponding":false},{"id":1612135,"name":"J.J. Sacco","orcid":null,"position":19,"is_corresponding":false},{"id":58256,"name":"P. Nathan","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)","abstract":null,"is_dataset_classified":null,"base_score":2.772588722239781,"endowment":2.772588722239781,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":"https://openalex.org/W2978410499","authors":[],"funders":[],"total_grants":0,"fwci":1.2523,"citation_percentile":0.7848974,"influential_citations":0,"citation_trend":[{"year":2020,"count":2},{"year":2021,"count":3},{"year":2022,"count":1},{"year":2023,"count":3},{"year":2024,"count":4},{"year":2025,"count":2}],"oa_status":"bronze","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"https://doi.org/10.1093/annonc/mdz394.070","host_type":"journal"},{"url":"https://doi.org/10.1093/annonc/mdz394.070","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0923753419604308?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0923753419604308?httpAccept=text/plain","host_type":"publisher"},{"url":"http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz394.070/30082702/mdz394.070.pdf","host_type":"publisher"},{"url":"https://research.manchester.ac.uk/en/publications/b1e22c93-db1a-4706-a6ab-d4b0400bd429","host_type":"repository"}],"fields_of_study":["Ocular Oncology and Treatments","Retinal Development and Disorders","Immunotherapy and Immune Responses"],"mesh_terms":[],"keywords":["Medicine","Selumetinib","MEK inhibitor","Paclitaxel","Melanoma","Metastatic melanoma","Oncology","Internal medicine","Chemotherapy","Pharmacology","Cancer research","Cancer","MAPK/ERK pathway","Kinase"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T01:10:34.355088Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}